Regeneron Pharmaceuticals, Inc.

The Royal Institution for the Advancement of Learning / Mcgill University

Olukayode Sosina

Aris I Baras

Luca Andrea Lotta

Parsa Akbari

Manuel Allen Revez Ferreira

Niek Verweij

Adam Locke

Jonas Nielsen

Jonas Bovijn

Sirui Zhou

John Brent Richards

Mary Haas

The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.

Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

The present disclosure provides methods of treating a subject having a liver disease or type 2 diabetes, and methods of identifying subjects having an increased risk of developing a liver disease or type 2 diabetes.

Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.

Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors

Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors

The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.

Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

Growing community of inventors

Tarrytown, NY, United States of America

Olukayode Sosina